FDA

FDA headquarters
#FDA #Orphan drugs #Osteosarcoma

FDA grants Orphan Drug Designation to osteosarcoma treatment 

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to a treatment for osteosarcoma.  SOT106, developed by biopharmaceutical company SOTIO Biotech, is a next-generation antibody-drug conjugate (ADC) targeting leucine-rich repeat-containing 15 (LRRC15), a clinically validated target broadly expressed across sarcoma subtypes and in tumour associated stroma.  Preclinical data… Read More

#News #Regulatory

Alzheimer's disease drug
#Alzheimer's #FDA #Herantis Pharma #Parkinson's

Herantis to advance Alzheimer’s treatment after FDA meeting 

Herantis is set to advance the clinical development of its Alzheimer’s therapy following a positive meeting with the US Food and Drug Administration (FDA).  The company reports it completed a pre-IND meeting with the FDA to discuss the planned clinical development of HER-096, a first-in-class small peptide being developed to… Read More

#News #Regulatory

#AI / data analytics / healthtech / informatics #EMA #FDA #Regulatory

Why pharma must refocus its data efforts if it really wants to exploit AI

Now that this industry is seriously looking to advanced automation to reinvent the work it does, the data transformation imperative has soared back up the strategic agenda, says Ian Crone, ArisGlobal’s VP Europe & APAC Regulatory Solutions. Here, he reports on an impassioned panel debate that took place as part of the Life Science AI Exchange Podcast last year. The panel included subject… Read More

#Exclusive Content #Opinion

#AstraZeneca #Drug discovery #Europe #European Federation of Pharmaceutical Industries and Associations #FDA #Francis Crick Institute #Hypertension #Lung cancer #Mental health #Tropical disease #University of Dundee #Wellcome Trust

DDW Highlights: 26 May 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a report showed patients in Europe face barriers to medicine access. Elsewhere,… Read More

#Podcasts

#AI #Autoimmune disease #Breast cancer #Clinical trial #Cystic fibrosis #Diabetes #FDA #Fractyl Health #Gene therapy #GLP-1 #Institute of Cancer Research #Oncology #Phesi

This week in Drug Discovery (18 – 22 May)

News round-up for 18 – 22 May by Bruno Quinney, Content Team at DDW.    This week, a report showed patients in Europe face barriers to patient access. Elsewhere, Wellcome prizes are facilitating research in both tropical disease and mental health.    The… Read More

#News

Europe
#Europe #European Federation of Pharmaceutical Industries and Associations #FDA

Patients in Europe face barriers to medicine access 

Patients in Europe are waiting longer to access medicines than patients in the US, a new report warns.  The European Federation of Pharmaceutical Industries and Associations (EFPIA)’s report shows 49% of FDA-approved medicines are not available in Europe, up from 46% in 2019.  Data also… Read More

#Editor's Choice #News #Regulatory

FDA headquarters
#AstraZeneca #FDA #Hypertension

FDA approves hypertension treatment in landmark step

The US Food and Drug Administration (FDA) has approved AstraZeneca’s Baxfendy (baxdrostat) in the US for the treatment of hypertension.  Baxfendy has been approved as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of hypertension in combination with other antihypertensive medications, to lower blood pressure in adults who are not… Read More

#News #Regulatory

#AI #Autoimmune disease #Breast cancer #Clinical trial #Cystic fibrosis #Diabetes #FDA #Fractyl Health #Gene therapy #GLP-1 #Institute of Cancer Research #Oncology #Phesi

DDW Highlights: 19 May 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, research uncovered new treatment pathways for hard to treat breast cancers. Elsewhere,… Read More

#Podcasts

Cell therapy platform
#FDA #Gene therapy #Manufacturing

Cytiva’s transcient cell line receives FDA AMT designation 

The US Food and Drug Administration (FDA) has given an advanced manufacturing technology (AMT) designation to Cytiva’s transient cell line, making it one of the first gene therapy manufacturing technologies to receive the designation.   The ELEVECTA transient cell line for adeno-associated virus (AAV) manufacturing is said to reduce the formation… Read More

#News #Regulatory

#AI #Autoimmune disease #Breast cancer #Clinical trial #Cystic fibrosis #Diabetes #FDA #Fractyl Health #Gene therapy #GLP-1 #Institute of Cancer Research #Oncology #Phesi

This week in Drug Discovery (11 – 15 May) 

News round-up for 11 – 15 May by Bruno Quinney, Content Team at DDW.  This week, research has uncovered new treatment pathways for hard to treat breast cancers. Elsewhere, therapies given the green light could combat type 2 diabetes and generalised myasthenia gravis.  The top stories:   … Read More

#News

Cell and gene therapy concept
#Cell and gene therapy #Eli Lilly #FDA #Novo Nordisk #Takeda #Tregs

A bright future for advanced therapies 

2025 was a difficult year for cell and gene therapies (CGTs), as multiple companies discontinued their cell therapy efforts, including Galapagos, Novo Nordisk and Takeda, despite significant financial losses as a result. The complexity and expense of manufacturing the treatments has meant that even when they are approved, the therapies do not always reach the relevant patients. This,… Read More

#Exclusive Content

#Autoimmune disease #Clinical trial #FDA

FDA treatment approval brings ‘hope’ to gMG patients 

The US Food and Drug Administration (FDA) has approved the first treatments for all serotypes of patients living with generalised myasthenia gravis (gMG).  The FDA’s label expansion of Vyvgart (efgartigimod alfa-fcab) and Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) now means gMG adult patients can treat all serotypes, including anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive,… Read More

#News #Regulatory

#AI #ALS #Cancer Research Horizons #Cancer Research UK #FDA #Malaria #Mergers and acquisitions #Oncology #Real-time clinical trials #Regulatory #Spinogenix #University of Bath #University of Leeds

DDW Highlights: 12 May 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, the FDA advanced an initiative to implement real-time clinical trials. Elsewhere, UCB made… Read More

#Podcasts

#AI #ALS #Cancer Research Horizons #Cancer Research UK #FDA #Malaria #Mergers and acquisitions #Oncology #Real-time clinical trials #Regulatory #Spinogenix #University of Bath #University of Leeds

This week in Drug Discovery (4 – 8 May) 

News round-up for 4 – 8 May by Bruno Quinney, Content Team at DDW.  This week, the FDA has advanced an initiative to implement real-time clinical trials. Elsewhere, UCB has made headlines for through an acquisition and its cancer research venture.  The top stories:    FDA moves… Read More

#News

#Breast cancer #Fast Track designation #FDA

FDA fast tracks immune medicine targeting breast cancer 

The US Food and Drug Administration (FDA) has granted Fast Tack Designation for an immune medicine targeting triple-negative breast cancer.  RPTR-1-201 is a novel T cell receptor (TCR) bispecific immune medicine, developed by biotechnology company Repertoire Immune Medicines, that is currently in a Phase I/II trial for the… Read More

#News #Regulatory